@article{3103444,
    title = "KDIGO Controversies Conference on onco-nephrology: kidney disease in hematological malignancies and the burden of cancer after kidney transplantation",
    author = "Małyszko, J. and Bamias, A. and Danesh, F.R. and Dębska-Ślizień, A. and Gallieni, M. and Gertz, M.A. and Kielstein, J.T. and Tesarova, P. and Wong, G. and Cheung, M. and Wheeler, D.C. and Winkelmayer, W.C. and Porta, C. and Abu-Alfa, A.K. and Amer, H. and Beutel, G. and Chapman, J. and Chen, X. and Chudek, J. and Cosmai, L. and Danesi, R. and De Stefano, F. and Iseki, K. and Jaimes, E.A. and Jhaveri, K.D. and Jurczyszyn, A. and Kazancioğlu, R. and Kitchlu, A. and Kollmannsberger, C. and Lahoti, A. and Li, Y. and Macía, M. and Matsubara, T. and Mitropoulos, D. and Noiri, E. and Perazella, M.A. and Ronco, P. and Rosner, M.H. and Soler Romeo, M.J. and Sprangers, B. and Stadler, W.M. and Stevens, P.E. and Tesař, V. and Torres da Costa e Silva, V. and Vesole, D.H. and Vijayan, A. and Viklický, O. and Workeneh, B.T. and Yanagita, M. and Zakharova, E. and Conference Participants",
    journal = "Kidney International",
    year = "2020",
    volume = "98",
    number = "6",
    pages = "1407-1418",
    publisher = "Elsevier B.V.",
    issn = "0085-2538, 1523-1755",
    doi = "10.1016/j.kint.2020.07.012",
    keywords = "allopurinol;  bisphosphonic acid derivative;  brentuximab vedotin;  calcineurin inhibitor;  carfilzomib;  dasatinib;  denosumab;  dinaciclib;  febuxostat;  flavopiridol;  lenalidomide;  oprozomib;  proteasome inhibitor;  rasburicase;  tacrolimus;  venetoclax;  xanthine oxidase inhibitor;  zoledronic acid, acute lymphoblastic leukemia;  amyloidosis;  anaplastic large cell lymphoma;  cancer screening;  Conference Paper;  decision making;  disease association;  disease burden;  disease registry;  drug efficacy;  drug safety;  estimated glomerular filtration rate;  extracorporeal oxygenation;  hematologic malignancy;  hemodialysis;  human;  hypertension;  kidney biopsy;  kidney disease;  kidney function;  kidney transplantation;  lymphoma;  monoclonal immunoglobulinemia;  multiple myeloma;  myeloma cast nephropathy;  nonhuman;  outcome assessment;  patient education;  priority journal;  risk assessment;  risk factor;  thrombocytopenia;  thrombotic thrombocytopenic purpura;  tumor lysis syndrome;  adverse event;  chronic kidney failure;  hematologic disease;  kidney;  neoplasm;  nephrology;  practice guideline, Hematologic Neoplasms;  Humans;  Kidney;  Kidney Transplantation;  Neoplasms;  Nephrology;  Renal Insufficiency, Chronic",
    abstract = "The bidirectional relationship between cancer and chronic kidney disease (CKD) is complex. Patients with cancer, particularly those with hematological malignancies such as multiple myeloma and lymphoma, are at increased risk of developing acute kidney injury and CKD. On the other hand, emerging evidence from large observational registry analyses have consistently shown that cancer risk is increased by at least 2- to 3-fold in kidney transplant recipients, and the observed increased risk occurs not only in those who have received kidney transplants but also in those on dialysis and with mild- to moderate-stage CKD. The interactions between cancer and CKD have raised major therapeutic and clinical challenges in the management of these patients. Given the magnitude of the problem and uncertainties, and current controversies within the existing evidence, Kidney Disease: Improving Global Outcomes (KDIGO) assembled a global panel of multidisciplinary clinical and scientific expertise for a controversies conference on onco-nephrology to identify key management issues in nephrology relevant to patients with malignancy. This report covers the discussed controversies in kidney disease in hematological malignancies, as well as cancer after kidney transplantation. An overview of future research priorities is also discussed. © 2020 Kidney Disease: Improving Global Outcomes (KDIGO)"
}